Veliparib (ABT-888)

Catalog No.S1004 Synonyms: NSC 737664

Veliparib (ABT-888) Chemical Structure

Molecular Weight(MW): 244.29

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Size Price Stock Quantity  
In DMSO USD 156 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 40 Publications

9 Customer Reviews

  • (A) OVCAR-8 cells were exposed to the indicated concentrations of FdUrd along with vehicle, 3 μM ABT-888 or 300 nM AZD2281 for 24 h. Following washing, ABT-888 and AZD2281 were re-added to the plates initially exposed to these agents, and cells were cultured in the continued presence of ABT-888 and AZD2281 for 8 d until colonies formed. (B) OVCAR-8 cells were exposed continuously to the indicated agents for 8 d. (C) OVCAR-8 cells treated as in (A) except that the indicated concentrations of ABT-888 were used.

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

    OVCAR-8 cells were plated, treated with indicated concentrations of FdUrd and 3 μM ABT-888 using the exposure schemes depicted in (C) and assayed for clonogenicity (D).

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046-1051. Veliparib (ABT-888) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

  • Colorimetric poly(ADP-ribose) polymerase (PARP) activity assay showing the relative activity of the PARP-1 enzyme in Raji lymphocyte tumor cells. Results show a highly significant difference in PARP activity in the controls [PBS and dimethyl sulfoxide (DMSO)] compared with 24 h incubation with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281. A significant increase in PARP enzyme activity is shown in DMSO-incubated cells compared with PBS control.* P < 0.05.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

    T47D breast cancer cells were pretreated with indicated concentrations of ABT-888

     

     

    Dr.Zhang of Tianjin Medical University. Veliparib (ABT-888) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor ABT-888 upon induction of DNA damage

    Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor ABT-888 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor.
    Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.
     
     

     

    David Schrmann from University of Base. Veliparib (ABT-888) purchased from Selleck.

    Caption:  451 Lu is a melanoma cell line with high PARP expression that is resistant to temozolomide.  Treatment with 25 µM ABT-888 greatly increased sensitivity to temozolomide compared to cells without ABT-888 treatment as measured by MTS assay.

     

     

    Dr. Steve Reuland from University of Colorado Denver. Veliparib (ABT-888) purchased from Selleck.

  • Effect of ABT-888 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     
     

     

    Dr. Xiangbing Meng of University of Iowa. Veliparib (ABT-888) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.
Features Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
In vitro

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 NV;2VFMzU2mwYYPlJGF{e2G7 MnnDN|AhdWmw NFTIWXVKdmirYnn0bY9vKG:oIGDBVnAyKHerdHigSWM2OCCxZjCwMlAxOiEQvF2= MkK5NVk5QDh5NkC=
Jurkat M4TnTGtqdmG|ZTDBd5NigQ>? M2Lq[Fk3KGh? Mn7ESG1UVw>? M3y2ZmlvcGmkaYTpc44hd2ZiUFHSVFEh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJINmdGxidnnhZoltcXS7IIfpeIghTUN3MDDv[kA{KM7:TR?= NXHFN41HOjN6NUCxPVk>
Capan1 M1zISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXrXHBPPzJiaB?= Ml;xSG1UVw>? MlnQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDCVmNCOiCpZX7lJI12fGG2ZXSgbJVu[W5iQ3HwZY4yKGOnbHzzJJdqfGhiSVO1NEBw\iB|OT63JO69VQ>? M1LJclI1Ozl6M{iz
DT40 NX3wdpZ7S3m2b4TvfIlkKEG|c3H5 M33zTlczKGh? NI[3TYhFVVOR MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBkcGmla3XuJGJTS0F{LXTl[olkcWWwdDDEWFQxKGOnbHzz Ml;3NlQ6OjJ3OEe=
ML-1 NEfyfVVCeG:ydH;0bYMhSXO|YYm= NXfhd4ZXOi53IN88US=> M3zxUlI1KGh? NGPvOZRFVVOR MYDTfY5memerc4TpZ4FtdHliZX7oZY5k\XNiVGLBTWwucW6mdXPl[EBieG:ydH;zbZMhcW5iTVytNUBk\Wyucx?= MXqyOFg6PTF|NR?=
HCT-116 MmDWT4lv[XOnIFHzd4F6 NXH5XYc2OC53IN88US=> MXmyOEBp NH7s[oNRSVKSIHHjeIl3cXS7IHTlZ5Jm[XOncx?= NIe2dYkzOzB3NEKxNy=>
UM-SCC1 MWPDfZRwfG:6aXOgRZN{[Xl? MnfWNVAh|ryP M1W5TlI1KGh? MmDXVoVlfWOnczD0bIUh[2WubDD2bYFjcWyrdIm= NYe4PYhHOjF7MUK2NlA>
FaDu Mn;mR5l1d3SxeHnjJGF{e2G7 NW\uSlRvOTBizszN MoP4NlQhcA>? NFq1XI9T\WS3Y3XzJJRp\SClZXzsJJZq[WKrbHn0fS=> MUeyNVkyOjZ{MB?=
PC-3 NWq3WY1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrFUHkyOCEQvF2= M1XEd2lv\HWlZYOgZUB{cWewaX\pZ4FvfCCrbnjpZol1cW:wIHnuJINwdG:weTDmc5Ju[XSrb39CpC=> NU\xUIhZOjF3N{G5NVI>
EoL-1-cell NGrpVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fGemlEPTB;MT6wO|k5KM7:TR?= MXjTRW5ITVJ?
NCI-SNU-5 NXSyWYJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13zcmlEPTB;Mz6xNlg1OSEQvF2= Mn7UV2FPT0WU
BV-173 M3K1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S0dGlEPTB;NT60OVQxQSEQvF2= MkX3V2FPT0WU
HCC1806 MmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXM[2hKSzVyPUWuO|UyPzNizszN NEfrNYZUSU6JRWK=
COLO-680 M2nwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XOSWlEPTB;Nj6yNVQxPiEQvF2= MUPTRW5ITVJ?
HCC2218 NFzoOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVq5fJF3UUN3ME23Mlc6PzB2IN88US=> NYDPeVF7W0GQR1XS
SK-MEL-24 NG\yVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnVPFhKSzVyPUeuPFE6OjRizszN NIPwTXRUSU6JRWK=
NCI-H720 NIDPWoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3G0RWlEPTB;OD60N|YxOyEQvF2= NE\abGpUSU6JRWK=
KASUMI-1 MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zne2lEPTB;OD64PVI3PiEQvF2= NXv4ZoNiW0GQR1XS
HAL-01 NGPHSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPnfGZKSzVyPUmuPFg3OiEQvF2= NELNfpJUSU6JRWK=
CAL-33 NXm1b414T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nSOmlEPTB;MUCuOFM1KM7:TR?= NGLSU|hUSU6JRWK=
SK-MEL-1 MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTF{LkS2OlMh|ryP NVvSW2ZGW0GQR1XS
Ramos-2G6-4C10 NVz6eYRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPCfmRLUUN3ME2xNk41PzV{IN88US=> MkOzV2FPT0WU
KY821 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjPVoRrUUN3ME2xNk41QDVizszN M3\Zb3NCVkeHUh?=
HEC-1 M3\KOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjWZ4JQUUN3ME2xNk46OTl4IN88US=> NGDkUppUSU6JRWK=
SK-NEP-1 M3vPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF|LkG2OkDPxE1? NHfsR|RUSU6JRWK=
MN-60 NW[2UIdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHm[VRuUUN3ME2xN{42Ozh7IN88US=> NYPwTpFCW0GQR1XS
DU-145 NHnZeFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP5TWM2OD1zMz65NFU{KM7:TR?= NXXrO2N[W0GQR1XS
EW-3 NYLTOHdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTF2LkW1OlUh|ryP MnvLV2FPT0WU
OS-RC-2 Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTF3Lkm1PFkh|ryP Mk\IV2FPT0WU
RPMI-8226 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjON4JTUUN3ME2xOk4zODR{IN88US=> MUTTRW5ITVJ?
ChaGo-K-1 MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fxbWlEPTB;MU[uOVMzPSEQvF2= MW\TRW5ITVJ?
DEL MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\wTodwUUN3ME2xOk43PzF5IN88US=> M13JbnNCVkeHUh?=
GP5d MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF5LkC1N{DPxE1? MlX0V2FPT0WU
COLO-668 MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXzSGhKSzVyPUG3MlYzQTRizszN NE\tfGNUSU6JRWK=
H9 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF6LkK4N|Mh|ryP NF7pRW5USU6JRWK=
NKM-1 Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\HTWM2OD1zOD61NVE6KM7:TR?= MlLzV2FPT0WU
KYSE-150 NF7DZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr2TZlKSzVyPUG4Mlk6QDZizszN M1HaVHNCVkeHUh?=
Daoy M2XwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:1WHBKSzVyPUG5MlU3PDlizszN M2nMbnNCVkeHUh?=
ECC10 NIrWcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\3dFZIUUN3ME2yNE44PDV3IN88US=> MVvTRW5ITVJ?
A388 NEPEXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[wSmlEPTB;MkGuPVA6OSEQvF2= NVvMemhLW0GQR1XS
MHH-NB-11 M1jUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPlTWM2OD1{Mz6xN|Y{KM7:TR?= NEe4dlhUSU6JRWK=
HCC1937 NXjVc5AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjF[YhHUUN3ME2yOE44PDZizszN NVPlZldzW0GQR1XS
TGBC11TKB MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLUTWM2OD1{NT62PFY{KM7:TR?= M3rSeXNCVkeHUh?=
CTV-1 M1jVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn5TWM2OD1{NT64PVY6KM7:TR?= Mk\5V2FPT0WU
NCI-H2029 NV:wOppTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTJ4LkSyN|gh|ryP NEjib2ZUSU6JRWK=
HLE NVv1OJdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf6T4U5UUN3ME2yO{4xPTRizszN MWjTRW5ITVJ?
NCI-H1693 NYLuNVhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJ5LkK4PVgh|ryP MV\TRW5ITVJ?
HCC70 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4POb2lEPTB;MkeuO|I1PiEQvF2= M4rXO3NCVkeHUh?=
BEN NHL0Vm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHuTXlQUUN3ME2yO{46PTZ4IN88US=> NUTzR2IxW0GQR1XS
LB771 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJ6LkizO|Mh|ryP NInkO2ZUSU6JRWK=
697 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H6eWlEPTB;MkmuNFI{PSEQvF2= MlPWV2FPT0WU
LU-139 NEmxT5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJ7LkO3OFgh|ryP NH\KOmVUSU6JRWK=
EW-13 M4DnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2H6RWlEPTB;MkmuN|gyPCEQvF2= NGTtNW5USU6JRWK=
MOLT-13 M3TwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PLZ2lEPTB;MkmuN|gyPCEQvF2= NUPCWHVTW0GQR1XS
L-363 M3XLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJ7LkS3PVgh|ryP NGLEOIdUSU6JRWK=
EM-2 M1jX[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPve4VKSzVyPUK5MlQ6ODFizszN NFPUfG1USU6JRWK=
RS4-11 MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XiXmlEPTB;M{CuOFI1OSEQvF2= NWfpR|N3W0GQR1XS
A2780 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTNyLke0OVch|ryP NHe5SJlUSU6JRWK=
KU812 NUfSPGY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUD1UIRxUUN3ME2zNk4{PjR{IN88US=> NEH6W|ZUSU6JRWK=
COLO-684 NFTNWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojOTWM2OD1|Mz6zOVk6KM7:TR?= M1u5cnNCVkeHUh?=
MFE-280 MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q5UmlEPTB;M{OuN|g5QSEQvF2= NEjLNpNUSU6JRWK=
KG-1 M1e0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTN|Lk[wNFEh|ryP NVTkb2V4W0GQR1XS
JVM-3 MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTQe4JKSzVyPUO1MlU5PjhizszN MlWzV2FPT0WU
MV-4-11 NYjq[Jd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrYUW5KSzVyPUO1Mlg1QTlizszN M1jzZnNCVkeHUh?=
LAMA-84 NFHod4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1GzZ2lEPTB;M{[uO|M1PSEQvF2= NX;zfVRzW0GQR1XS
MOLT-16 MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfMZ3NKSzVyPUO2Mlk2OiEQvF2= MmfXV2FPT0WU
H4 MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zFOGlEPTB;M{euOVY4KM7:TR?= MmLhV2FPT0WU
T47D MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH6UI1KSzVyPUO3MlcxOThizszN MUPTRW5ITVJ?
CAL-54 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nzXWlEPTB;M{euPVY3KM7:TR?= Mn[4V2FPT0WU
SW982 NFWye21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnuTWM2OD1|OD6wPVk5KM7:TR?= MWXTRW5ITVJ?
IGROV-1 M4i4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkW4TWM2OD1|OT6zN|A1KM7:TR?= M37JenNCVkeHUh?=
NB14 M2HGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTCd3dKSzVyPUSwMlcxOzFizszN MXnTRW5ITVJ?
HCC1187 M2H6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTRzLkK3O|Eh|ryP NUTY[2l3W0GQR1XS
SBC-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXMWFVKSzVyPUSxMlMxPjNizszN M1fqe3NCVkeHUh?=
KARPAS-45 M4L0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vacGlEPTB;NEGuOFgyQCEQvF2= M4W2dHNCVkeHUh?=
MOLT-4 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLMTXo4UUN3ME20Nk4zPTN6IN88US=> NX;EZoNXW0GQR1XS
JVM-2 MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4mwbGlEPTB;NEKuPVIxPyEQvF2= NWS1dGVwW0GQR1XS
A4-Fuk MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS1U5lYUUN3ME20N{42PjlzIN88US=> NWL6Rnp5W0GQR1XS
MDA-MB-361 NFTRUVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTR|Lki0NVQh|ryP NFW2WYFUSU6JRWK=
BALL-1 NULnWGxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILtXGNKSzVyPUSzMlk2OzJizszN MnrsV2FPT0WU
T98G NGPlR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M12yemlEPTB;NESuPFUyPyEQvF2= NYLXbWxNW0GQR1XS
Mo-T MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPy[2VKSzVyPUS1MlY{QDlizszN NYD3fZhFW0GQR1XS
MHH-PREB-1 MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPDWGFnUUN3ME20OU44PTh3IN88US=> MnzxV2FPT0WU
ALL-PO MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTR5LkO3PVEh|ryP NVX5dXJtW0GQR1XS
NCI-H510A MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3VdmZ[UUN3ME20O{46ODN2IN88US=> M1TIWXNCVkeHUh?=
ML-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTR7Lke4OVYh|ryP NH\VWVFUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

Protocol

Animal Research:

[1]

+ Expand
  • Animal Models: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • Formulation: Formulated in solution containing 0.9% NaCl adjusted to pH 4.0
  • Dosages: ~25 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
0.5% methylcellulose+0.2% Tween 80
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.29
Formula

C13H16N4O

CAS No. 912444-00-9
Storage powder
Synonyms NSC 737664

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00553189 Completed Solid Tumors|Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9, 2007 Phase 1
NCT03032614 Not yet recruiting Breast Cancer Stage IV|Ovarian Cancer|BRCA1 Mutation|BRCA2 Mutation The University of Texas Health Science Center at San Antonio March 31, 2017 Phase 2
NCT01445522 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 3, 2008 Phase 1
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT02723864 Recruiting Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 22, 2016 Phase 1
NCT00994071 Completed Medulloblastoma|Pontine Glioma|Ependymoma|Astrocytoma|PNET National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) September 22, 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Veliparib (ABT-888) | Veliparib (ABT-888) supplier | purchase Veliparib (ABT-888) | Veliparib (ABT-888) cost | Veliparib (ABT-888) manufacturer | order Veliparib (ABT-888) | Veliparib (ABT-888) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID